GT Biopharma, Inc. — SEC Form D Filing

GT Biopharma, Inc. filed an SEC Form D on September 29, 2026, reporting $7.75M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
September 29, 2026
Amount reported
$7.75M
Round stage
Series B+
Industry
Biotechnology
Website
https://www.gtbiopharma.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Cancer cells need to be selectively killed, and there is an unmet need for innovative therapies to target various oncology indications, including multiple myeloma.

Solution

GT Biopharma is developing therapies based on its proprietary NK cell engager (TriKE®) technology, which are targeted immunotherapeutic agents designed to facilitate the killing of cancer cells by simultaneously reacting with NK cells and cancer cells.

Verdict

Investors funded GT Biopharma based on a clear, if early, technology platform applying a known mechanism (NK cell engagement) to a high-value problem in oncology. This cleared because the approach offered a credible new modality in a crowded therapeutic area, not because it presented a fully de-risked clinical profile. They were implicitly betting on the biological validity and platform extensibility of TriKE®, anticipating future clinical milestones and partnerships to validate market potential. The upside was limited by the inherent long timelines and high capital requirements typical of early-stage biopharma, where clinical outcomes remain uncertain.

Source: SEC EDGAR Form D filing